These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8865 related articles for article (PubMed ID: 12962010)

  • 21. Immunotherapy for pancreatic cancer: current concepts.
    Kaufman HL; Di Vito J; Hörig H
    Hematol Oncol Clin North Am; 2002 Feb; 16(1):159-97, viii. PubMed ID: 12063825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer vaccines.
    Butterfield LH
    BMJ; 2015 Apr; 350():h988. PubMed ID: 25904595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.
    Wakabayashi R; Sakuragi M; Kozaka S; Tahara Y; Kamiya N; Goto M
    Mol Pharm; 2018 Mar; 15(3):955-961. PubMed ID: 29397746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer vaccines inducing antibody production: more pros than cons.
    Jensen-Jarolim E; Singer J
    Expert Rev Vaccines; 2011 Sep; 10(9):1281-9. PubMed ID: 21919618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
    Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
    Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical models and technologies to advance nanovaccine development.
    Peres C; Matos AI; Moura LIF; Acúrcio RC; Carreira B; Pozzi S; Vaskovich-Koubi D; Kleiner R; Satchi-Fainaro R; Florindo HF
    Adv Drug Deliv Rev; 2021 May; 172():148-182. PubMed ID: 33711401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer immunotherapy: moving forward with peptide T cell vaccines.
    Kumai T; Fan A; Harabuchi Y; Celis E
    Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colorectal cancer vaccines: Tumor-associated antigens
    Wagner S; Mullins CS; Linnebacher M
    World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoprevention of cancer: time to reconsider timing of vaccination against cancer.
    Spisek R
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1689-91. PubMed ID: 17181481
    [No Abstract]   [Full Text] [Related]  

  • 33. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving role of tumor antigens for future melanoma therapies.
    Andrews MC; Woods K; Cebon J; Behren A
    Future Oncol; 2014 Jun; 10(8):1457-68. PubMed ID: 25052755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
    Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlates of immune and clinical activity of novel cancer vaccines.
    van der Burg SH
    Semin Immunol; 2018 Oct; 39():119-136. PubMed ID: 29709421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.
    Wages NA; Slingluff CL; Petroni GR
    Contemp Clin Trials; 2015 Mar; 41():172-9. PubMed ID: 25638752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 444.